## Psychedelics and Neurostimulation for Brain Rewiring

## Key Takeaways
1. **Depression is a complex and disabling condition**: It can manifest in various ways, is a risk factor for other illnesses, and makes other conditions worse. 
2. **The brain-heart connection is a real and measurable phenomenon**: Stimulation of the left dorsolateral prefrontal cortex (DLPFC) slows heart rate and can alleviate depressive symptoms, suggesting a potential circuit for mood regulation.
3. **The prefrontal cortex plays a critical role in cognitive control and rule-switching**: It can be influenced by talk therapy and potentially by TMS, which may help "re-script" negative beliefs and restore order to the brain.
4. **Ketamine's antidepressant effects may not be solely due to its dissociative properties**: Blocking the opioid system with naltrexone significantly reduces ketamine's antidepressant effects but does not affect its dissociative effects, indicating the opioid system's involvement in mood regulation.
5. **Psilocybin and other psychedelics have potential as treatments for depression and trauma**: They appear to induce long-lasting changes in brain connectivity and may work by promoting a "letting go" state, allowing individuals to re-examine and potentially re-script negative memories and beliefs.
6. **Cannabis can exacerbate psychosis in certain individuals, especially during brain development**: High doses of THC are pro-psychotic, while CBD is anti-psychotic and anti-epileptic.  
7. **Stanford Neuromodulation Therapy (SNT) offers a promising new approach to treating depression**: It utilizes TMS delivered in a spaced learning pattern, aiming to "retrain" the brain's circuitry within 5 days. 

## Introduction
This episode of the Huberman Lab Podcast features Dr. Nolan Williams, a triple board-certified psychiatrist, neurologist, and professor of psychiatry and behavioral sciences at Stanford School of Medicine. Dr. Williams, the director of the Stanford Brain Stimulation Lab, discusses his research on using neurostimulation techniques, including transcranial magnetic stimulation (TMS), in combination with psychedelics to treat depression, trauma, and other mood disorders. He shares unique insights into the brain-heart connection, the role of the prefrontal cortex in cognitive control and rule-switching, and the neurochemistry of psychedelics. Dr. Williams also provides valuable insights into the use of ibogaine, ayahuasca, and cannabis in a clinical setting. 

[Link to the full episode](https://www.youtube.com/watch?v=X4QE6t-MkYE)

### Depression, Risk Factors, Emergency Psychiatric Treatments (0:09:16)
- Depression is a highly disabling condition, impacting both physical and mental health.
- It's the fourth major risk factor for coronary artery disease, and its presence increases the risk of developing depression after a heart attack.
- Current treatment options for severe depression are limited, especially in emergency settings.
- Dr. Williams highlights the need for new, brain-based solutions to address this critical gap in care.

### The Brain-Heart Connection, Vagus Nerve, Prefrontal Cortex (0:15:11)
- Stimulation of the left DLPFC directly impacts the heart rate, decelerating it, suggesting a physical connection between the brain's control region and the heart.
- This connection may be a key component in mood regulation, as the left DLPFC is associated with reducing depressive symptoms, while the right DLPFC is linked to mania.
- The human connectome project has identified a strong correlation between lesions that cause depression and those that cause mania with the left and right DLPFC, respectively.

### Heart Rate & Depression, Behavioral Interventions, Transcranial Magnetic Stimulation (TMS) (0:22:34)
-  Stimulating the vagus nerve, a cranial nerve connected to the DLPFC through the cingulate and insula, can also alleviate depressive symptoms, further supporting the role of this network in mood regulation.
- Behavioral interventions like exhale-emphasized breathing and exercise can be effective in mild depression, potentially working through the same heart-brain connection.
- TMS, a non-invasive brain stimulation technique, can directly stimulate or inhibit specific brain circuits, providing a tool to study and potentially treat depression.

### Prefrontal Cortex & Cognitive Control, TMS (0:33:02)
- The left DLPFC is involved in cognitive control, including rule-switching, as seen in the Stroop task.
- TMS can be used to inhibit specific regions of the prefrontal cortex, increasing trait hypnotizability and altering cognitive function.
- This suggests that the prefrontal cortex might play a role in accessing and potentially modifying beliefs, which can be key in overcoming depression.

### Belief/Identity “Rules”, Re-scripting, TMS & Talk Therapy (0:39:00)
-  Depression may involve fixed negative beliefs or "rules" about oneself, which can be difficult to change with willpower alone.
-  Talk therapy, by helping individuals identify and re-script these negative beliefs, may work through a similar mechanism to the rule-switching that occurs in the prefrontal cortex.
- TMS may serve as an exogenous method for promoting cognitive flexibility and overriding the influence of negative beliefs in severe depression.

### Dorsolateral Prefrontal Cortex, TMS & Depression Treatment (0:45:49)
- The DLPFC acts as a "governor" for the brain, shaping how we interpret physiological signals and spontaneous thoughts. 
- TMS can be viewed as a form of "exercise" for the brain, strengthening the DLPFC's ability to regulate other brain regions.
-  In some individuals, TMS has been observed to induce mindfulness-like experiences, suggesting a potential for promoting self-awareness and emotional regulation.

### Cingulate Cortex & Emotion, Dissociation & Catatonia (0:48:36)
- The anterior cingulate cortex (ACC) is involved in conflict detection and emotional processing.
-  Overactivity in the ACC is linked to obsessive-compulsive disorder, and the ACC's role in regulating emotions may explain why individuals with depression experience heightened anxiety.
- Damage to the cingulate can lead to akinetic mutism, a state of immobility and lack of communication, suggesting its critical role in connecting with reality.
-  Dissociative states, often seen in PTSD and trauma, may involve dysfunction in the cingulate and could be related to the "letting go" phenomenon observed during psychedelic journeys.

### Ketamine, the Opioid System & Depression; Psychedelic Experience or Biology? (0:54:27)
- Ketamine, a dissociative anesthetic, shows a correlation between its level of dissociative effects and its antidepressant effects.
- Blocking the opioid system with naltrexone significantly reduces ketamine's antidepressant effects, indicating the importance of the opioid system in its therapeutic actions.
-  This finding challenges the notion that the psychological experience of a psychedelic is solely responsible for its therapeutic effects, suggesting that underlying pharmacology may play a crucial role.

### SSRIs, Serotonin & Depression; Childhood, Chemical Imbalance or Circuit? (1:03:42)
- There is no direct link between serotonin levels and depression, despite SSRIs' effectiveness for some individuals.
- The delayed onset of action for SSRIs suggests that their effects may be mediated by changes in brain plasticity, potentially involving the upregulation of neurotrophic factors like brain-derived neurotrophic factor (BDNF).
- The "chemical imbalance" theory of depression is outdated and may be detrimental to patients, as it promotes a sense of being fundamentally broken.
- Psychiatry 3.0 focuses on brain circuitry and recognizes depression as a recoverable condition, emphasizing the importance of recalibrating neural networks.

### Memories & “Rule” Creation; Psilocybin & “Rule” Resolution (1:13:58)
- The brain may hold onto negative memories and beliefs for evolutionary reasons, but these can be maladaptive in modern society.
- Psychedelics like psilocybin, by disrupting typical thought patterns and sensory processing, may allow individuals to access and re-examine these negative memories and beliefs in a new light.
-  The "letting go" phenomenon observed during psychedelic journeys may facilitate the rescripting of these rules and lead to long-lasting relief from trauma and depression.

### MDMA & Post-Traumatic Stress Disorder (PTSD) Treatment, Psilocybin & Depression Treatment (1:21:00)
- MDMA, when administered in controlled clinical settings, shows promising results in treating PTSD, with significant improvement in symptoms observed in about 2/3 of individuals after one or two sessions.
- Psilocybin has shown potential as a treatment for depression, with promising results in both open-label and blinded trials.
- The potential for long-lasting effects of MDMA and psilocybin, compared to the shorter-lasting effects of ketamine, suggests a possible shift in brain circuitry.

### Is MDMA Neurotoxic?, Drug Purity, Dopamine Surges, Post-MDMA Prolactin (1:24:12)
- Research has debunked the notion that MDMA is neurotoxic to serotonin neurons at appropriate doses and with high purity. 
- Studies on individuals who solely use MDMA have shown no significant neurocognitive differences compared to individuals who do not use the substance. 
- The post-MDMA fatigue might be related to the surge in prolactin following a dopamine surge, rather than serotonin depletion. 

### Psilocybin, Brain Connectivity & Depression Treatment (1:30:38)
- Psilocybin, acting primarily on the 5HT2A serotonin receptor, induces changes in brain connectivity, potentially explaining its psychedelic effects.
-  Research has shown an increase in global brain connectivity and a decrease in overall brain activity under the influence of psilocybin.
-  Psilocybin's antidepressant effects seem to involve a change in connectivity between the subgenual anterior cingulate and the default mode network, suggesting a potential for decoupling the negative self-representation from emotional conflict.

### Exposure Response Prevention: “Letting Go” & Depression Treatment (1:34:53)
-  Exposure response prevention therapy (ERP), a traditional treatment for OCD, involves intentionally exposing individuals to anxiety-provoking situations and then allowing them to "let go" of their compulsions. 
-  The "letting go" phenomenon observed during psychedelic journeys may be similar to ERP, promoting a state where individuals can detach from their habitual reactions and negative beliefs.
-  This may allow for a "reset" of the brain's circuitry, leading to a new perspective and potential relief from depression and trauma.

### Normal Spectrums for Mental Health Disorders (1:41:23)
- "Normal" mental health is not defined as a complete absence of symptoms but rather a range of experiences that do not significantly impair an individual's functioning.
-  Many people experience mild, subclinical forms of mental health challenges like obsessive-compulsive tendencies that do not require clinical intervention.
-  Talking openly about these experiences can help reduce stigma and foster a sense of shared experience.

### Ibogaine & “Life Review”; PTSD, Depression & Clinical Trials (1:45:35)
- Ibogaine, an alkaloid extracted from the iboga tree root bark, is used sacramentally in Gabon and has a unique psychedelic effect that involves re-experiencing past memories from a detached, empathic perspective.
-  It is not a recreational substance and is associated with a "life review" experience that can be emotionally challenging but potentially therapeutic.
-  Clinical trials are investigating ibogaine's potential for treating PTSD, depression, and addiction.
-  Ibogaine's potential cardiac effects necessitate careful screening and administration under medical supervision.

### Clinical Use of Psychedelics (1:57:16)
- Psychedelics, when used in controlled clinical settings, show promise for treating mental health conditions that have been challenging to address with traditional therapies.
- Their ability to disrupt habitual thinking patterns and facilitate a "letting go" state may allow for a re-examination of negative memories and beliefs.
-  However, the powerful nature of psychedelics necessitates strict medical supervision and precautions to prevent potential misuse or adverse effects.

### Ayahuasca, Brazilian Prisoner Study (2:01:59)
- Ayahuasca, a psychedelic brew made from a combination of two plants, contains DMT, a powerful psychedelic compound. 
-  It is used sacramentally in South American cultures and has been explored as a potential treatment for depression.
- A study in Brazilian prisons found that ayahuasca sessions were associated with significantly lower recidivism rates, suggesting a possible impact on behavior and decision-making.

### Cannabis: THC, CBD & Psychosis, Clinical Uses (2:06:55)
- Cannabis contains various cannabinoids, including THC, which is pro-psychotic and pro-epileptic, and CBD, which is anti-psychotic and anti-epileptic.
-  The relative balance of THC and CBD can determine the effects of cannabis, with high THC strains being more likely to induce psychosis in susceptible individuals.
-  CBD has shown potential as a treatment for epilepsy, particularly in children with Dravet syndrome and Lennox-Gastaut syndrome, and as an adjunctive treatment for schizophrenia.
-  Early use of potent cannabis, especially before prefrontal maturation, is associated with an increased risk of psychosis later in life. 

### Personal Relative Drug Risk & Alcohol (2:14:52)
-  Alcohol, due to its high personal and societal risks, is considered the most dangerous drug in the world according to a study published in The Lancet.
-  Despite its prevalence and perceived "normality," alcohol is associated with a range of health risks and has a significant impact on individual and societal well-being. 
-  The ubiquity of alcohol consumption within healthcare institutions and university campuses suggests a need for societal reevaluation of its role and risks.

### Circadian Reset for Depression, Sleep Deprivation, Light (2:20:42)
- Sleep deprivation, particularly REM sleep deprivation, can temporarily alleviate symptoms of depression.
-  Chronic sleep deprivation can disrupt the autonomic nervous system and increase anxiety.
-  Circadian rhythm disruption is a core feature of depression, and re-setting the circadian system through sleep deprivation, light exposure, and phase shifting may provide durable antidepressant effects.

### Stanford Neuromodulation Therapy (SNT) Study (2:28:43)
-  Stanford Neuromodulation Therapy (SNT), formerly known as Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), is a novel TMS protocol based on space learning theory.
-  It utilizes high-intensity TMS delivered in a spaced pattern, aiming to deliver the equivalent of 7 1/2 months of traditional TMS therapy in just five days.
-  SNT has shown promising results in treating depression, with 60-90% of patients achieving full remission within 5 days.
-  The study is ongoing and recruiting participants, with access to the treatment provided through various clinical trials across the country.

## Practical Advice and Strategies
- **Prioritize sleep hygiene**: Aim for consistent sleep-wake times, minimize blue light exposure before bed, and create a relaxing bedtime routine.
- **Engage in regular exercise**: Physical activity can improve mood and potentially work through the heart-brain connection.
- **Consider talk therapy**: Therapy can help identify and re-script negative beliefs and promote emotional regulation.
- **Practice mindfulness and stress reduction techniques**: Mindfulness meditation and deep breathing exercises can help regulate the autonomic nervous system and promote a sense of calm.
- **Explore the potential benefits of light therapy**: Light exposure can help re-set the circadian rhythm and potentially improve mood.

## Tools and Resources Mentioned
- **BSL (Brain Stimulation Lab) at Stanford**: [https://bsl.stanford.edu/](https://bsl.stanford.edu/) - Offers clinical trials for depression and other mood disorders. 
- **Huberman Lab Premium**: [https://hubermanlab.com/premium](https://hubermanlab.com/premium) - Provides additional content, including AMAs, transcripts, and tools for health optimization. 
- **Momentous Supplements**: [https://livemomentous.com/huberman](https://livemomentous.com/huberman) - Offers supplements related to sleep, focus, and performance.

## Articles
- **"Cannabis use in adolescence and risk of psychotic disorder: a systematic review"** -  Published in Lancet Psychiatry (2022) - Discusses the link between early cannabis use and increased risk of psychosis.
- **"Ketamine blocks the antidepressant effects of repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex in humans"** -  Published in JAMA Psychiatry (2016) -  Demonstrates the role of the opioid system in mediating ketamine's antidepressant effects.
- **"The role of serotonin in depression: a critical review"** - Published in Frontiers in Psychiatry (2016) -  Challenges the "chemical imbalance" theory of depression and explores other potential mechanisms.

## Books
- **Breaking Open the Head by Daniel Pinchbeck**: Explores the history and use of ibogaine in Gabon.

## Other Resources
- **Veterans Solutions**: A group pioneering psychedelic treatments for former and current special operators.
- **GW Pharmaceuticals**: A company developing CBD-based medications for epilepsy and other conditions.

#### Hashtags  
#Depression #TMS #Neuromodulation #Psychedelics #Ketamine #Psilocybin #MDMA #Ibogaine #Ayahuasca #Cannabis #CBD #THC #Sleep #CircadianRhythm #BrainHeartConnection #PrefrontalCortex #CingulateCortex #PTSD #Trauma #Addiction #MentalHealth 
